
Labcorp Holdings (LH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
3.3B
Gross Profit
948.0M
28.34%
Operating Income
332.4M
9.94%
Net Income
213.0M
6.37%
EPS (Diluted)
$2.52
Balance Sheet Metrics
Total Assets
17.6B
Total Liabilities
9.3B
Shareholders Equity
8.3B
Debt to Equity
1.12
Cash Flow Metrics
Operating Cash Flow
148.2M
Free Cash Flow
-107.5M
Revenue & Profitability Trend
Labcorp Holdings Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 13.0B | 12.2B | 11.9B | 13.1B | 14.0B |
Cost of Goods Sold | 9.4B | 8.8B | 8.2B | 8.1B | 9.0B |
Gross Profit | 3.6B | 3.4B | 3.7B | 5.0B | 5.0B |
Gross Margin % | 27.9% | 27.7% | 31.3% | 38.0% | 35.4% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 2.2B | 2.0B | 1.8B | 1.7B | 1.7B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 2.2B | 2.0B | 1.8B | 1.7B | 1.7B |
Operating Income | 1.1B | 1.1B | 1.8B | 3.1B | 2.9B |
Operating Margin % | 8.7% | 9.2% | 14.8% | 23.4% | 21.1% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 208.3M | 199.6M | 179.8M | 211.8M | 207.4M |
Other Non-Operating Income | 29.8M | -355.2M | -335.0M | 26.8M | -521.6M |
Pre-tax Income | 959.5M | 568.9M | 1.2B | 2.9B | 2.2B |
Income Tax | 212.4M | 188.5M | 233.9M | 690.0M | 662.1M |
Effective Tax Rate % | 22.1% | 33.1% | 18.9% | 23.9% | 29.8% |
Net Income | 747.1M | 419.2M | 1.3B | 2.4B | 1.6B |
Net Margin % | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% |
Key Metrics | |||||
EBITDA | 1.8B | 1.7B | 2.3B | 3.7B | 3.5B |
EPS (Basic) | $8.89 | $4.80 | $14.05 | $24.60 | $15.99 |
EPS (Diluted) | $8.84 | $4.77 | $13.97 | $24.39 | $15.88 |
Basic Shares Outstanding | 83900000 | 87100000 | 91100000 | 96700000 | 97300000 |
Diluted Shares Outstanding | 83900000 | 87100000 | 91100000 | 96700000 | 97300000 |
Income Statement Trend
Labcorp Holdings Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.5B | 536.8M | 320.6M | 1.5B | 1.3B |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.9B | 1.9B | 1.8B | 2.3B | 2.5B |
Inventory | 493.2M | 474.6M | 470.6M | 401.4M | 423.2M |
Other Current Assets | 697.6M | 655.3M | 610.4M | 478.1M | 364.8M |
Total Current Assets | 4.8B | 3.8B | 4.6B | 5.3B | 5.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 784.5M | 737.1M | 738.1M | 746.3M | 789.8M |
Goodwill | 16.2B | 15.6B | 15.4B | 19.7B | 19.5B |
Intangible Assets | 3.5B | 3.3B | 3.1B | 3.7B | 4.0B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 652.2M | 536.5M | 3.4B | 484.2M | 430.6M |
Total Non-Current Assets | 13.6B | 13.0B | 15.5B | 15.1B | 14.9B |
Total Assets | 18.4B | 16.7B | 20.2B | 20.4B | 20.1B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 875.8M | 827.5M | 852.2M | 621.3M | 638.9M |
Short-term Debt | 1.2B | 1.2B | 471.1M | 199.0M | 575.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | 657.6M | - | - |
Total Current Liabilities | 3.3B | 3.2B | 3.1B | 2.8B | 3.1B |
Non-Current Liabilities | |||||
Long-term Debt | 6.1B | 4.8B | 5.8B | 6.1B | 6.2B |
Deferred Tax Liabilities | 383.1M | 417.9M | 543.4M | 762.9M | 828.5M |
Other Non-Current Liabilities | 136.2M | 142.3M | 161.3M | 81.1M | 216.7M |
Total Non-Current Liabilities | 7.0B | 5.6B | 7.0B | 7.3B | 7.5B |
Total Liabilities | 10.3B | 8.8B | 10.0B | 10.1B | 10.6B |
Equity | |||||
Common Stock | 7.6M | 7.7M | 8.1M | 8.5M | 9.0M |
Retained Earnings | 8.3B | 7.9B | 10.6B | 10.5B | 9.5B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.1B | 7.9B | 10.1B | 10.3B | 9.5B |
Key Metrics | |||||
Total Debt | 7.3B | 6.0B | 6.2B | 6.3B | 6.8B |
Working Capital | 1.5B | 540.2M | 1.5B | 2.5B | 2.0B |
Balance Sheet Composition
Labcorp Holdings Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 747.1M | 380.4M | 1.0B | 2.2B | 1.6B |
Depreciation & Amortization | 643.5M | 577.3M | 537.2M | 577.0M | 624.7M |
Stock-Based Compensation | 116.7M | 128.7M | 116.8M | 132.9M | 111.7M |
Working Capital Changes | 13.0M | -12.9M | 330.8M | 227.6M | -1.1B |
Operating Cash Flow | 1.7B | 1.2B | 2.2B | 3.2B | 1.4B |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | -823.9M | -671.5M | -1.2B | -496.9M | -267.6M |
Investment Purchases | -55.0M | -29.0M | -17.4M | -27.8M | -40.1M |
Investment Sales | 0 | 6.7M | 8.1M | 13.2M | 4.1M |
Investing Cash Flow | -876.9M | -693.2M | -1.2B | -424.2M | -261.5M |
Financing Activities | |||||
Share Repurchases | -250.1M | -1.0B | -1.1B | -1.7B | -100.0M |
Dividends Paid | -243.1M | -254.0M | -195.2M | 0 | 0 |
Debt Issuance | 4.5B | 2.5B | 787.4M | 1.0B | 0 |
Debt Repayment | -3.5B | -2.8B | -787.4M | -1.4B | -563.9M |
Financing Cash Flow | 723.7M | -1.6B | -534.8M | -2.1B | -517.4M |
Free Cash Flow | 1.1B | 874.1M | 1.5B | 2.7B | 1.8B |
Net Change in Cash | 1.6B | -1.0B | 505.0M | 737.7M | 641.8M |
Cash Flow Trend
Labcorp Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
30.67
Forward P/E
17.36
Price to Book
2.72
Price to Sales
1.71
PEG Ratio
1.83
Profitability Ratios
Profit Margin
5.66%
Operating Margin
11.30%
Return on Equity
9.26%
Return on Assets
4.44%
Financial Health
Current Ratio
1.50
Debt to Equity
77.78
Beta
0.76
Per Share Data
EPS (TTM)
$9.07
Book Value per Share
$102.20
Revenue per Share
$161.29
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
lh | 23.1B | 30.67 | 2.72 | 9.26% | 5.66% | 77.78 |
Thermo Fisher | 188.8B | 28.95 | 3.74 | 13.42% | 15.24% | 69.62 |
Danaher | 151.7B | 45.06 | 2.90 | 6.68% | 14.21% | 35.45 |
Idexx Laboratories | 51.6B | 53.75 | 35.47 | 64.87% | 24.41% | 84.81 |
Agilent Technologies | 34.6B | 29.96 | 5.63 | 18.88% | 17.59% | 60.04 |
Iqvia Holdings | 32.5B | 27.70 | 5.62 | 19.79% | 7.88% | 272.12 |
Financial data is updated regularly. All figures are in the company's reporting currency.